共 50 条
The future trajectory of adverse outcome pathways: a commentary
被引:0
|作者:
Fiona Sewell
Nichola Gellatly
Maria Beaumont
Natalie Burden
Richard Currie
Lolke de Haan
Thomas H. Hutchinson
Miriam Jacobs
Catherine Mahony
Ian Malcomber
Jyotigna Mehta
Graham Whale
Ian Kimber
机构:
[1] National Centre for the Replacement,School of Geography, Earth and Environmental Sciences
[2] Refinement and Reduction of Animals in Research (NC3Rs),Faculty of Biology, Medicine and Health
[3] GlaxoSmithKline,undefined
[4] Syngenta Ltd.,undefined
[5] Jealott’s Hill International Research Centre,undefined
[6] MedImmune,undefined
[7] University of Plymouth,undefined
[8] Public Health England,undefined
[9] Procter and Gamble Company,undefined
[10] Unilever,undefined
[11] Safety and Environmental Assurance Centre,undefined
[12] Dow AgroSciences,undefined
[13] European Development Centre,undefined
[14] Shell,undefined
[15] Health,undefined
[16] Shell Centre,undefined
[17] University of Manchester,undefined
来源:
关键词:
Adverse outcome pathways (AOPs);
Hazard identification;
Safety assessment;
Risk assessment;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis for addressing some of those challenges and opportunities.
引用
收藏
页码:1657 / 1661
页数:4
相关论文